Cross-sectional studies in adult patients have demonstrated an association between circulating levels of GH and IGF-I and NAFLD severity [31–33], leading to speculative hypotheses about a role of these molecules as predictive markers or therapeutic targets in NAFLD. Here, GH1 is linked to metabolic dysfunction-associated steatotic liver disease.